Molecular Fingerprinting in Cancer

• Conditions: C34; C61; C50; C67; C56; C00-C14; C18; C22; C25; Malignant neoplasm of bronchus and lung

• Registration Number: DRKS00013217
• Lead Sponsor: udwig-Maximilians Universität München, Fakultät für Physik,

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-11-21
• Results First Posted: 2021-10-26
• Study Completion: 2021-12-21
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 3479

Inclusion Criteria

• Adults > 18 years who are able to consent to this study.
• For tumor patients: confirmed tumor located in the lung, prostate, breast, head or neck.
• For control group: patients with benign diagnoses.
• The study participant has consented to participation in this study

Exclusion Criteria

Patients who are not able to consent

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
• Area underneath the receiver operating characteristic function (AUC) of spectral features (GMFs) for discriminating blood samples of patients with confirmed lung, prostate, breast, and head and neck carcinoma and control patients with other pathologies. Spectral features are derived using laser-based infrared spectrosopy.

Secondary Outcome Measures

Name	Time	Method
• Proteomic profiles from mass spectrometry of blood samples of patients with confirmed lung, prostate and breast<br>carcinoma and patients with other diseases.<br>• Routine clinical data, including medical imaging data and currently used biomarkers, of patients with confirmed lung, prostate and breast carcinoma and patients with other diseases.